CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) ...

About VINCOBODIES VINCOBODIES are an advancement in antibody engineering ... the development of next-generation multivalent VHH VINCOBODIES to conquer unmet medical needs in cancer and immunology.

de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique Biologics CDMO providing biological drug development ...

de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods ...

Scinai Immunotherapeutics Ltd. ("Scinai" or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through ...

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and contract development and manufacturing (CDMO) services, ...

Researchers from Vicero Inc. have developed a Vincobody platform, which allows for design of novel proprietary VHH antibody fragments that possess the efficacy of dual checkpoint blockade while ...

Late-breaker poster presentation at the inaugural AACR IO underscores potential of VCR-036, a novel PD-1/CTLA-4 VHH antibody for treatment of solid tumors Being developed to solve limitations due to ...